TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• TransMedics Group, Inc. has received a consensus recommendation of “Moderate Buy” from nine research firms, with an average price target of $123.00 for the next year.
• In recent analyst activity, Canaccord Genuity raised its price target for the company from $129.00 to $142.00, while Oppenheimer increased its target from $130.00 to $150.00.
• The company's latest quarterly earnings showed revenue of $157.37 million, exceeding expectations, and it reported a significant year-over-year revenue increase of 37.7%.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $123.00.

Several equities research analysts have recently commented on TMDX shares. Canaccord Genuity Group increased their price objective on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday. Morgan Stanley boosted their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Oppenheimer boosted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Finally, Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.00% of the company's stock.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of the stock. Amalgamated Bank grew its position in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company's stock worth $1,285,000 after buying an additional 80 shares during the period. Canada Pension Plan Investment Board increased its position in shares of TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock valued at $482,000 after acquiring an additional 100 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock valued at $72,000 after purchasing an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in TransMedics Group by 4.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company's stock valued at $455,000 after purchasing an additional 142 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in TransMedics Group by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,842 shares of the company's stock valued at $1,989,000 after buying an additional 148 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Price Performance

NASDAQ TMDX opened at $114.96 on Friday. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $172.78. The company has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.09. The firm's 50 day moving average is $120.24 and its 200-day moving average is $103.07.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.